Compare Stocks: ATOS, ANIX, GUTS, and ATRA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANIX Anixa Biosciences	$2.77 +0.4%	$3.30	$2.32 ▼ $5.46	$96.30M	0.51	346,323 shs	315,202 shs
ATOS Atossa Genetics	$2.22 -7.5%	$2.44	$1.70 ▼ $19.35	$22.15M	1.27	41,865 shs	39,577 shs
ATRA Atara Biotherapeutics	$9.69 -0.2%	$8.93	$3.92 ▼ $19.15	$97.27M	0.1	46,720 shs	37,766 shs
GUTS Fractyl Health	$0.60 +1.6%	$0.71	$0.38 ▼ $2.45	$95.51M	2.34	1.60 million shs	1.81 million shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANIX Anixa Biosciences	+0.36%	+0.36%	-25.34%	-4.81%	-17.31%
ATOS Atossa Genetics	-7.50%	-11.55%	-15.91%	+10.45%	-82.17%
ATRA Atara Biotherapeutics	-0.21%	+3.30%	+0.94%	-3.77%	-16.39%
GUTS Fractyl Health	+1.56%	-6.25%	-12.54%	-28.99%	-38.29%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANIX Anixa Biosciences	$2.77 +0.4%	$3.30	$2.32 ▼ $5.46	$96.30M	0.51	346,323 shs	315,202 shs
ATOS Atossa Genetics	$2.22 -7.5%	$2.44	$1.70 ▼ $19.35	$22.15M	1.27	41,865 shs	39,577 shs
ATRA Atara Biotherapeutics	$9.69 -0.2%	$8.93	$3.92 ▼ $19.15	$97.27M	0.1	46,720 shs	37,766 shs
GUTS Fractyl Health	$0.60 +1.6%	$0.71	$0.38 ▼ $2.45	$95.51M	2.34	1.60 million shs	1.81 million shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANIX Anixa Biosciences	+0.36%	+0.36%	-25.34%	-4.81%	-17.31%
ATOS Atossa Genetics	-7.50%	-11.55%	-15.91%	+10.45%	-82.17%
ATRA Atara Biotherapeutics	-0.21%	+3.30%	+0.94%	-3.77%	-16.39%
GUTS Fractyl Health	+1.56%	-6.25%	-12.54%	-28.99%	-38.29%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANIX Anixa Biosciences	2.40	Hold	$10.00	261.01% Upside
ATOS Atossa Genetics	2.20	Hold	$20.33	815.92% Upside
ATRA Atara Biotherapeutics	2.50	Moderate Buy	$9.50	-1.96% Downside
GUTS Fractyl Health	2.40	Hold	$5.50	816.67% Upside

Current Analyst Ratings Breakdown

Latest ATOS, ANIX, GUTS, and ATRA Analyst Ratings

Date	Company	Brokerage	Action	Rating
9/17/2026	ANIX Anixa Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
9/8/2026	ATOS Atossa Genetics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
9/3/2026	ANIX Anixa Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
9/3/2026	GUTS Fractyl Health	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/24/2026	ATRA Atara Biotherapeutics	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/20/2026	GUTS Fractyl Health	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/19/2026	ANIX Anixa Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/19/2026	ANIX Anixa Biosciences	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/18/2026	ATRA Atara Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/6/2026	GUTS Fractyl Health	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/31/2026	ATRA Atara Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)

(Data available from 9/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANIX Anixa Biosciences	$210K	458.50	N/A	N/A	$0.38 per share	7.29
ATOS Atossa Genetics	N/A	N/A	N/A	N/A	$4.57 per share	N/A
ATRA Atara Biotherapeutics	$120.77M	0.81	$4.87 per share	1.99	($5.34) per share	-1.81
GUTS Fractyl Health	$90K	1,061.20	N/A	N/A	$0.07 per share	8.57

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANIX Anixa Biosciences	-$10.93M	-$0.32	N/A	N/A	N/A	N/A	-76.59%	-67.80%	N/A
ATOS Atossa Genetics	-$34.77M	-$3.11	N/A	N/A	N/A	N/A	-102.99%	-85.78%	11/11/2026 (Estimated)
ATRA Atara Biotherapeutics	$32.69M	-$1.18	N/A	7.02	N/A	-269.42%	-79.12%	-73.01%	10/29/2026 (Estimated)
GUTS Fractyl Health	-$140.95M	-$0.88	N/A	N/A	N/A	N/A	-1,362.10%	-84.89%	11/11/2026 (Estimated)

Latest ATOS, ANIX, GUTS, and ATRA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/9/2026	Q3 2026	ANIX Anixa Biosciences	-$0.0818	-$0.08	+$0.0018	-$0.08	N/A	N/A
8/12/2026	Q2 2026	ATRA Atara Biotherapeutics	-$0.3150	-$0.32	-$0.0050	-$0.32	$0.55 million	$0.63 million
8/10/2026	Q2 2026	GUTS Fractyl Health	-$0.1350	-$0.12	+$0.0150	-$0.16	N/A	N/A
8/7/2026	Q2 2026	ATOS Atossa Genetics	-$1.02	-$0.95	+$0.07	-$0.95	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANIX Anixa Biosciences	N/A	N/A	N/A	N/A	N/A
ATOS Atossa Genetics	N/A	N/A	N/A	N/A	N/A
ATRA Atara Biotherapeutics	N/A	N/A	N/A	N/A	N/A
GUTS Fractyl Health	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANIX Anixa Biosciences	N/A	8.55	8.54
ATOS Atossa Genetics	N/A	5.69	5.14
ATRA Atara Biotherapeutics	N/A	1.98	1.98
GUTS Fractyl Health	1.41	3.15	3.15

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANIX Anixa Biosciences	29.13%
ATOS Atossa Genetics	12.74%
ATRA Atara Biotherapeutics	70.90%
GUTS Fractyl Health	N/A

Insider Ownership

Company	Insider Ownership
ANIX Anixa Biosciences	26.40%
ATOS Atossa Genetics	9.80%
ATRA Atara Biotherapeutics	41.20%
GUTS Fractyl Health	8.36%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANIX Anixa Biosciences	4	34.76 million	25.59 million	Optionable
ATOS Atossa Genetics	14	9.98 million	9.00 million	Optionable
ATRA Atara Biotherapeutics	330	10.04 million	5.90 million	No Data
GUTS Fractyl Health	73	159.18 million	145.87 million	N/A

ATOS, ANIX, GUTS, and ATRA Headlines

Recent News About These Companies

GUTS INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Fractyl Investors of Securities Class Action Lawsuit Deadline on October 20, 2026

September 19 at 8:21 AM | newsfilecorp.comN

Fractyl Health, Inc. (GUTS) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

September 18 at 1:15 PM | prnewswire.com $https://www.prnewswire.com/news-releases/fractyl-health-inc-guts-shareholders-who-lost-money-have-opportunity-to-lead-securities-fraud-lawsuit-302882447.html$

Bronstein, Gewirtz & Grossman LLC Urges Fractyl Health, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

September 18 at 12:00 PM | globenewswire.com $https://www.globenewswire.com/news-release/2026/09/18/3364874/9788/en/bronstein-gewirtz-grossman-llc-urges-fractyl-health-inc-investors-to-act-class-action-filed-alleging-investor-harm.html$

Fractyl Health, Inc. (NASDAQ:GUTS) Given Average Rating of "Hold" by Analysts

September 18 at 6:13 AM | marketbeat.com $https://www.marketbeat.com/instant-alerts/consensus-fractyl-health-inc-nasdaq-guts-given-average-rating-of-hold-by-analysts-2026-09-18/$

Bronstein, Gewirtz & Grossman LLC Urges Fractyl Health, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

September 17 at 12:00 PM | globenewswire.com $https://www.globenewswire.com/news-release/2026/09/17/3364262/9788/en/bronstein-gewirtz-grossman-llc-urges-fractyl-health-inc-investors-to-act-class-action-filed-alleging-investor-harm.html$

Faruqi & Faruqi, LLP Urges Fractyl Health, Inc. (GUTS) Investors to Seek Counsel Before the October 20, 2026 Lead Plaintiff Deadline in the Securities Class Action

September 17 at 10:24 AM | newsfilecorp.comN

GUTS DEADLINE: SueWallSt Reminds Fractyl Health, Inc. Investors of Upcoming Securities Class Action Deadline

September 17 at 10:07 AM | prnewswire.com $https://www.prnewswire.com/news-releases/guts-deadline-suewallst-reminds-fractyl-health-inc-investors-of-upcoming-securities-class-action-deadline-302881710.html$

Pomerantz Law Firm Announces the Filing of a Class Action Against Fractyl Health, Inc. and Certain Officers - GUTS

September 17 at 10:00 AM | prnewswire.com $https://www.prnewswire.com/news-releases/pomerantz-law-firm-announces-the-filing-of-a-class-action-against-fractyl-health-inc-and-certain-officers--guts-302881574.html$

SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Fractyl Health, Inc. (GUTS)

September 17 at 8:17 AM | globenewswire.com $https://www.globenewswire.com/news-release/2026/09/17/3363945/0/en/shareholder-alert-bernstein-liebhard-llp-announces-a-securities-fraud-class-action-lawsuit-has-been-filed-against-fractyl-health-inc-guts.html$

GUTS Stockholders Have Rights - If you Lost Money Investing in Fractyl Health, Inc. Contact Robbins LLP for Information About Recovering Your Losses

September 16 at 10:13 PM | tmcnet.com

GUTS Stockholders Have Rights – If you Lost Money Investing in Fractyl Health, Inc. Contact Robbins LLP for Information About Recovering Your Losses

September 16 at 7:33 PM | businesswire.com $https://www.businesswire.com/news/home/20260916265777/en/guts-stockholders-have-rights-%e2%80%93-if-you-lost-money-investing-in-fractyl-health-inc.-contact-robbins-llp-for-information-about-recovering-your-losses/$

GUTS SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds Fractyl Investors of Securities Class Action Lawsuit Deadline on October 20, 2026

September 16 at 10:13 AM | newsfilecorp.comN

GUTS Shareholder Alert: Fractyl Health, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact Levi & Korsinsky

September 16 at 10:07 AM | prnewswire.com $https://www.prnewswire.com/news-releases/guts-shareholder-alert-fractyl-health-inc-securities-class-action-lawsuit---investors-with-losses-may-contact-levi--korsinsky-302880064.html$

Comparing Fractyl Health (NASDAQ:GUTS) and TG Therapeutics (NASDAQ:TGTX)

September 16 at 2:16 AM | americanbankingnews.com

Pomerantz Law Firm Announces the Filing of a Class Action Against Fractyl Health, Inc. and Certain Officers – GUTS

September 15, 2026 | globenewswire.com $https://www.globenewswire.com/news-release/2026/09/15/3362680/1087/en/pomerantz-law-firm-announces-the-filing-of-a-class-action-against-fractyl-health-inc-and-certain-officers-guts.html$

Bronstein, Gewirtz & Grossman LLC Urges Fractyl Health, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

September 15, 2026 | globenewswire.com $https://www.globenewswire.com/news-release/2026/09/15/3362509/9788/en/bronstein-gewirtz-grossman-llc-urges-fractyl-health-inc-investors-to-act-class-action-filed-alleging-investor-harm.html$

SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of October 20, 2026 in Fractyl Health, Inc. Lawsuit - GUTS

September 15, 2026 | globenewswire.com $https://www.globenewswire.com/news-release/2026/09/15/3362413/0/en/suewallst-reminds-shareholders-of-a-lead-plaintiff-deadline-of-october-20-2026-in-fractyl-health-inc-lawsuit-guts.html$

FRACTYL HEALTH, INC. INVESTORS WITH LOSSES HAVE UNTIL OCTOBER 20, 2026 TO JOIN SECURITIES CLASS ACTION – Bernstein Liebhard LLP Announces Deadline

September 15, 2026 | globenewswire.com $https://www.globenewswire.com/news-release/2026/09/15/3362262/0/en/fractyl-health-inc-investors-with-losses-have-until-october-20-2026-to-join-securities-class-action-bernstein-liebhard-llp-announces-deadline.html$

Fractyl Health, Inc. (GUTS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

September 14, 2026 | seekingalpha.com $https://seekingalpha.com/article/4946255-fractyl-health-inc-guts-presents-at-morgan-stanley-24th-annual-global-healthcare-conference$

Deadline Alert: Fractyl Health, Inc. (GUTS) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit

September 14, 2026 | globenewswire.com $https://www.globenewswire.com/news-release/2026/09/14/3361462/34548/en/deadline-alert-fractyl-health-inc-guts-shareholders-who-lost-money-urged-to-contact-glancy-prongay-wolke-rotter-llp-about-securities-fraud-lawsuit.html$

Levi & Korsinsky Reminds Fractyl Health, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of October 20, 2026 - GUTS

September 14, 2026 | globenewswire.com $https://www.globenewswire.com/news-release/2026/09/14/3361438/3080/en/levi-korsinsky-reminds-fractyl-health-inc-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-october-20-2026-guts.html$

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ATOS, ANIX, GUTS, and ATRA Company Descriptions

Anixa Biosciences NASDAQ:ANIX

$2.77 +0.01 (+0.36%)

As of 09/18/2026 04:00 PM Eastern

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.

Atossa Genetics NASDAQ:ATOS

$2.22 -0.18 (-7.50%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$2.28 +0.06 (+2.93%)

As of 09/18/2026 07:30 PM Eastern

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.

Atara Biotherapeutics NASDAQ:ATRA

$9.69 -0.02 (-0.21%)

As of 09/18/2026 04:00 PM Eastern

Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.

Fractyl Health NASDAQ:GUTS

$0.60 +0.01 (+1.56%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$0.60 +0.00 (+0.17%)

As of 09/18/2026 07:59 PM Eastern

Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It also develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is headquartered in Burlington, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ATOS, ANIX, GUTS, and ATRA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ATOS, ANIX, GUTS, and ATRA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ATOS, ANIX, GUTS, and ATRA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ATOS, ANIX, GUTS, and ATRA Company Descriptions

Anixa Biosciences NASDAQ:ANIX

Atossa Genetics NASDAQ:ATOS

Atara Biotherapeutics NASDAQ:ATRA

Fractyl Health NASDAQ:GUTS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ATOS, ANIX, GUTS, and ATRA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ATOS, ANIX, GUTS, and ATRA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ATOS, ANIX, GUTS, and ATRA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ATOS, ANIX, GUTS, and ATRA Company Descriptions

Anixa Biosciences NASDAQ:ANIX

Atossa Genetics NASDAQ:ATOS

Atara Biotherapeutics NASDAQ:ATRA

Fractyl Health NASDAQ:GUTS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools